Pages Columns Lines where

PTO/SB/06a (05-07)
Approved for use through 09/00/2007 OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Is a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no pens

	Application Number		10613819	
	Filing Date		2003-07-03	
INFORMATION DISCLOSURE	First Named Inventor KIRK		KOR SIRINYAN	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1623	
	Examiner Name ELU		J PESELEV	
	Attorney Docket Numb	er	31923C2 (BHCA 132723)	

U.S.PATENTS

Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Da	ate	Name of Pate of cited Docu	entee or Applicant iment	Releva	,Columns,Line ant Passages : s Appear	or Relevant
	1	5994331		1999-11-	-30	ERDELEN, ET	ΓAL			
	2	5034404		1991-07-	-23	HIDEKI UNEW	ME, ET AL			
	3	5030650		1991-07-	-09	BUCKWALTE	R, ET AL.			
If you wis	h to a	dd additional U.S. Pater	nt citatio	n informa	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT A	APPLIC	CATION PUB	LICATIONS		Remove	
Examiner	Cite	Publication Number	Kind	Publicat	ion	Name of Pate	entee or Applicant		Columns,Line	
Initial*	No	Publication Number	Code <sup>1</sup>	Date		of cited Docu	iment		s Appear	or Kelevant
Initial*	No 1	Publication Number	Code <sup>1</sup>	Date			iment			or Kelevant
	1	dd additional U.S. Publi			citation	of cited Docu		Figure	s Appear	or Relevant
	1		shed Ap	plication		of cited Docu	please click the Ad	Figure	s Appear	or Kelevant
	1 h to a		shed Ap	plication		of cited Docu	please click the Ad	Figure d button	s Appear	is,Lines it T <sup>5</sup>

### 

	2	02221621A	GB			CAMPBELL, ET AL.		
	3	09533453A1	wo			MENCKE, ET AL.		
	4	09638165A2	wo			MENCKE, ET AL.		
	5	09638165A3	wo			MENCKE, ET AL.		
	6	08402571A	ZA			CAMPBELL, ET AL.		
	7	2251914	CA			SENN, ET AL.		
	8	09740692	wo			SENN, ET AL.		
	9	09528370A1	wo			SCHUTTE, ET AL.		
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
			NON-PATEN	NT LITE	RATURE DO	CUMENTS	Remove	
Evenines	Cita	Include name of the a	uthor (in CAPITA	AL LET	TERS), title of	the article (when appropr	iate), title of the ite	m

Examiner Cite Include name of the author (in CAPTALE LETTERS), till of the article (when appropriate), till of the limitals No (lock, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), production of the control of the c

### 

	EXAMINER SIGNATURE		
Examiner Signature		Date Considered	
	reference considered, whether or not citation is in conformation and not considered. Include copy of this form with		

See Kinc Ooke of USPTO Patent Documents at www.ISPTO.GOV or MPEP 901.04. I Enter office that issued the document, by the Involvation (WIPO Standard S13.) "Extra office This papers operated counters, the involvation of the year of the integer or impreced the serial running represent the serial running of the Empirer name precede the serial running of the Empirer name precede the serial running of the Empirer name precedes the serial running of the Empirer name of the Empirer

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit

Application Number		10613819		
Filing Date		2003-07-03		
First Named Inventor	KIRK	OR SIRINYAN		
Art Unit		1623		
Examiner Name ELLI F		PESELEV		
Attorney Docket Number		31923C2 (BHCA 132723)		

### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the appro	priate selection(s	s):
---------------	----------	-------------	----------------	--------------------	-----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

ionii oi tile signatare.			
Signature	/JEAN M. DICKMAN/	Date (YYYY-MM-DD)	2007-06-26
Name/Print	Jean M. Dickman	Registration Number	48538

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2313-1450. DIN OTS CRID FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.